Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

Drug-repurposing Identified the Combination of Trolox C and Cytisine for the Treatment of Type 2 Diabetes

In Silico Prediction of Potential Drug Combinations for Type 2 Diabetes Mellitus by an Integrated Network and Transcriptome Analysis

CMap Analysis Identifies Atractyloside As a Potential Drug Candidate for Type 2 Diabetes Based on Integration of Metabolomics and Transcriptomics

Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity

A drug repurposing method based on inhibition effect on gene regulatory network

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Single-cell Transcriptomics, Web-based Systems Pharmacology and Integrated Transcriptomics Network Analysis Identified Diagnostic Targets and Drug Candidates for Type 2 Diabetes

Comprehensive Network Analysis Reveals the Targets and Potential Multitarget Drugs of Type 2 Diabetes Mellitus.

Integrated edge information and pathway topology for drug-disease associations

Drug Repurposing for Cancer Treatment Through Global Propagation with a Greedy Algorithm in a Multilayer Network

Drug Repurposing: An Effective Tool in Modern Drug Discovery

Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer

Integrating population-level and cell-based signatures for drug repositioning

DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing

Prediction and evaluation of combination pharmacotherapy using natural language processing, machine learning and patient electronic health records

Prediction Of Candidate Drugs For Treating Pancreatic Cancer By Using A Combined Approach

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics

A Drug-Target Network-Based Approach to Evaluate the Efficacy of Medicinal Plants for Type Ii Diabetes Mellitus

Modeling Compound-Target Interaction Network of Traditional Chinese Medicines for Type II Diabetes Mellitus: Insight for Polypharmacology and Drug Design.